Exelixis Stock

Exelixis EBITDA

The EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Exelixis (EXEL) as of Aug 12, 2026 is 872.19 M USD. In the previous year, EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) was 604.62 M USD — a change of 44.26% (higher).

EBITDA

872.19 MUSD

YoY

44.26%

Last updated:

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Exelixis is 2026 872.19 M USD. EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Exelixis was 2025 604.62 M USD. It decreases by 44.26% higher compared to the previous year.
Access this data via the Eulerpool API

Exelixis Stock analysis

What does Exelixis do? Exelixis Inc. is a biopharmaceutical company that specializes in researching and developing drugs for various types of cancer. The company was founded in 1994 and is headquartered in Alameda, California. It has brought several drugs to the market over the years that have had a positive impact on thousands of patients. The company's founders, Corey Goodman, George Scangos, and John Walker, previously worked at Genentech and decided to start their own company to focus on cancer research and drug development. Exelixis Inc. has had numerous successes since its inception, including the development of Cabozantinib, a drug used to treat various types of cancer such as thyroid cancer, kidney cancer, and advanced prostate cancer. The company also has several drug candidates in clinical testing. Its business model revolves around researching and developing drugs that target proteins and signaling pathways overactivated in cancer cells. Exelixis Inc. often collaborates with other companies in the pharmaceutical industry to share development costs and risks. The company is divided into different divisions to treat various cancer types, including kidney, liver, thyroid, and lung cancer. One of its significant milestones was the approval of Cabozantinib by the FDA in 2012 for the treatment of advanced kidney and thyroid cancer. The drug has since been approved in other countries and has been successful in treating different types of cancer. Exelixis Inc. is dedicated to developing better and more effective cancer drugs to help patients. It works closely with doctors, researchers, and other pharmaceutical companies to constantly explore new approaches to combat cancer cells. In summary, Exelixis Inc. is a leading player in the research and development of drugs for various types of cancer. It has a track record of approved drugs and a pipeline of innovative drug candidates. The company's goal is to help cancer patients and contribute to improving people's health. Exelixis is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Exelixis stock

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Exelixis is 872.19 M USD in 2026.

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) of Exelixis changed from 604.62 M USD to 872.19 M USD, representing a 44.26% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization) Exelixis since 2006 – with annual values, charts, and detailed analysis.

EBITDA measures operating performance before the impact of financial structure, tax environment, and non-cash depreciation charges.

EBITDA = EBIT + Depreciation & Amortization

EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track EBITDA (Earnings Before Interest, Taxes, Depreciation & Amortization)'s Exelixis historically and in real time.

Access this data via the Eulerpool API

Income Statement — Exelixis

All Key Metrics — Exelixis